Conclusions
Application of topical mometasone prior to SC elamipretide
administration demonstrated a significant reduction in ISR signs induced
by elamipretide and did not cause significant changes in elamipretide
plasma exposure or additional adverse events. Further investigation of
mometasone is warranted for mitigation of elamipretide-induced ISRs and
improving compliance. Treatment options that target mast cell activation
may ameliorate elamipretide ISRs and should also be explored in future
studies.